MetaCap

Neurocrine Biosciences (NBIX) News

NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

150.57-6.02 (-3.84%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NBIX news summary

We found 50 recent headlines mentioning Neurocrine Biosciences (NBIX): 3 in the past week and 30 in the past 30 days, most often from Nasdaq, Seeking Alpha, PR Newswire. For price context, NBIX is down 3.84% at $150.57. The most recent story, "Neurocrine Biosciences (NBIX) is a Top-Ranked Momentum Stock: Should You Buy?", was published by Nasdaq on Nov 20, 2026.

Headlines link to the original publishers. MetaCap does not republish third-party articles.

Summary generated from market data by MetaCap's automated system. Methodology

Latest Neurocrine Biosciences headlines

Stocks mentioned alongside NBIX

Compare NBIX